Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands

    Question

    Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands

    Direct answer

    Eli Lilly's metabolic portfolio continues to expand, with Mounjaro and Zepbound driving $27.7 billion in 1H 2026 revenue. Formulary adoption of Foundayo provides an oral growth leg that expands the addressable patient base beyond injectable formats. The 7% monthly pullback in LLY shares reflects profit-taking and multiple compression across large-cap healthcare as 10-year yields approach 5%, rather than deterioration in underlying prescription momentum.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-glp-1-revenue-hits-27-7b-in-1h-2026-as-oral-foundayo-expands-7a2e76

    EQUITY
    Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
    Eli Lilly's metabolic portfolio continues to expand, with Mounjaro and Zepbound driving $27.7 billion in 1H 2026 revenue. Formulary adoption of Foundayo provides an oral growth leg that expands the addressable patient base beyond injectable formats. The 7% monthly pullback in LLY shares reflects profit-taking and multiple compression across large-cap healthcare as 10-year yields approach 5%, rather than deterioration in underlying prescription momentum.
    LLYNVO
    Impact
    70
    SEP 18
    SIG
    85%
    LLYNVO
    Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
    Eli Lilly's metabolic portfolio continues to expand, with Mounjaro and Zepbound driving $27.7 billion in 1H 2026 revenue. Formulary adoption of Foundayo provides an oral growth leg that expands the addressable patient base beyond injectable formats. The 7% monthly pullback in LLY shares reflects profit-taking and multiple compression across large-cap healthcare as 10-year yields approach 5%, rather than deterioration in underlying prescription momentum.
    → Securing national PBM reimbursement for oral GLP-1 therapy Foundayo increases volume access and long-term pharmaceutical franchise cash flows for LLY.
    Impact
    Eli Lilly's metabolic portfolio continues to expand, with Mounjaro and Zepbound driving $27.7 billion in 1H 2026 revenue. Formulary adoption of Foundayo provides an oral growth leg that expands the addressable patient base beyond injectable formats. The 7% monthly pullback in LLY shares reflects profit-taking and multiple compression across large-cap healthcare as 10-year yields approach 5%, rather than deterioration in underlying prescription momentum.
    Affected
    LLYNVO
    Transmission
    Securing national PBM reimbursement for oral GLP-1 therapy Foundayo increases volume access and long-term pharmaceutical franchise cash flows for LLY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYprescription volume growth and commercial formulary tier accessUp1-3mGLP-1 franchise generated $27.7B in 1H 2026 sales with expanding PBM coverage for Foundayo.
    NVOobesity and diabetes market share competitionWatch1-4wDirect competitor Eli Lilly added oral drug PBM access in the GLP-1 category.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOWatch43.24 2026-09-18-7.96%-10.27%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month